About
Targeted Tumor Drug Delivery Technology
Areas of Focus
Categories
Drug Delivery DeviceSeattle/Pacific Northwest
Clinical Trials (10)
View allTotal Trials
10
As Lead Sponsor
9
As Collaborator
1
Total Enrollment
106
By Phase
EARLY_PHASE1: 8PHASE1: 2
By Status
COMPLETED: 6RECRUITING: 2TERMINATED: 1WITHDRAWN: 1
Clinical Trials Pipeline10 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
Today
Hover over trial bars to see details
Recent Trials
NCT06366451Lead Sponsor
PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC
EARLY_PHASE1Recruiting
15 participants
Started: May 22, 2024 · Completed: Apr 30, 2025
NCT06273852Collaborator
A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors
EARLY_PHASE1Completed
8 participants
Started: Apr 29, 2024 · Completed: Mar 31, 2025
NCT06413095Lead Sponsor
PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS
EARLY_PHASE1Completed
13 participants
Started: Jun 1, 2022 · Completed: Jun 22, 2023
NCT04272333Lead Sponsor
Intratumoral Microdosing of Motolimod in HNSCC
EARLY_PHASE1Terminated
1 participants
Started: Oct 15, 2021 · Completed: Mar 25, 2022
NCT04891718Lead Sponsor
CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia
EARLY_PHASE1Withdrawn
Started: Sep 15, 2021 · Completed: Jun 5, 2022
Locations (1)
Headquarters
Seattle, WA, United States
Map
Loading map...